

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<b><i>Complete if Known</i></b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<i>Application Number</i>	10/568,098
				<i>Filing Date</i>	6/20/2006
				<i>First Named Inventor</i>	Steffen Goletz
				<i>Art Unit</i>	1636
				<i>Examiner Name</i>	Daniel M. Sullivan
Sheet	1	of	2	<i>Attorney Docket Number</i>	08358.0008-00000

## **U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS**

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

## **NONPATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
/ML/		AGRAWAL, et al. "Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2." <i>Natl. Med.</i> , 4(1):43-9 (1998)	
/ML/		DALL'OLIO, et al., "Expression of beta-galactoside alpha 2,6-sialyltransferase does not alter the susceptibility of human colon cancer cells to NK-mediated cell lysis." <i>Glycobiology</i> . 7:507-513 (1997)	
		GOLETAZ, et al., "Antigen: the hidden tumour antigen." <i>Adv. Exp. Med. Biol.</i> , 505:147-62 (2000) 	
		NATALI, et al., <i>Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells</i> . <i>Cancer Res</i> 1983; 43:660-666	
		PAHLSSON, et al., "Biochemical characterization of the O-glycans on recombinant glycophorin as expressed in Chinese hamster ovary cells." <i>Clycoconj. J.</i> , 11:43-50 (1994)	
		PETERS, et al., "Preparation of immuno-therapeutic autologous tumour cell vaccines from solid tumours." <i>Cancer Res</i> , 39:1353-1360 (1979)	
		SPRINGER, et al., "Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy." <i>J. Mol. Med.</i> , 75:594-602 (1997)	
		VAN RINSUM, et al., "Specific inhibition of human natural killer cell-mediated cytotoxicity by sialic acid and sialo-oligosaccharides." <i>Int. J. Cancer</i> , 38:915-922 (1986)	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<b><i>Complete if Known</i></b>	
				Application Number	10/568,098
				Filing Date	6/20/2006
				First Named Inventor	Steffen Goletz
				Art Unit	1636
				Examiner Name	Daniel M. Sullivan
Sheet	2	of	2	Attorney Docket Number	08358.0008-00000

<b>NONPATENT LITERATURE DOCUMENTS</b>				
/ML/		VOSHOL, et al., "Cell surface glycoconjugates as possible target structures for human natural killer cells: evidence against the involvement of glycolipids and N-linked carbohydrate chains." <i>Glycobiology</i> , 3:69-76 (1993)		
↓		WANG, et al., "Second-generation adenovirus vectors." <i>Nat. Med.</i> , 2:714-716 (1996)		
↓		WERKMEISTER, et al., "Modulation of K562 cells with sodium butyrate. Association of impaired NK susceptibility with sialic acid and analysis of other parameters." <i>Int. J. Cancer</i> , 32:71-78 (1983)		
↓		YU, et al., "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells." <i>Proc. Natl. Acad. Sci.</i> , 99:6047-6052 (1999)		
↓		ZHANG, et al., "A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells." <i>Cellular Immunology</i> , 176:156-165 (1997)		

Examiner Signature	/Maria Leavitt/	Date Considered	01/15/2009
--------------------	-----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.